Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy
BMC Pulmonary Medicine(2024)
Abstract
Monoclonal antibodies (biologics) drastically changed severe asthma therapy. Mepolizumab (anti-interleukin (IL) 5), benralizumab (anti-IL5 receptor alpha), and dupilumab (anti-IL4/13) are the most used biologics in this context. While all biologics are efficient individually, the choice of biologic is complicated by insufficient data on their comparative long-term treatment efficacy. Here, we compare the real-life efficacy of these biologics in asthma therapy over 12 months. 280 severe asthma patients treated with mepolizumab (129/280, 46
MoreTranslated text
Key words
Severe asthma,Long-term treatment response,Mepolizumab,Benralizumab,Dupilumab,Biologic Asthma Response Score
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined